These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 3573954

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Chemotherapy of leprosy. Report of a WHO Study Group.
    World Health Organ Tech Rep Ser; 1994; 847():1-24. PubMed ID: 7817604
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Blister calendar packs--potential for improvement in the supply and utilization of multiple drug therapy in leprosy control programs.
    Georgiev GD, McDougall AC.
    Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):603-10. PubMed ID: 3221116
    [No Abstract] [Full Text] [Related]

  • 27. Recent developments in the chemotherapy of leprosy.
    McDougall AC.
    Lepr Rev; 1997 Dec; 68(4):294-8. PubMed ID: 9503864
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Stigma, chemoprophylaxis, and leprosy control.
    Senior K.
    Lancet Infect Dis; 2009 Jan; 9(1):10. PubMed ID: 19145699
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A comparison of the incidence of type 2 reactions in lepromatous leprosy with two regimens of treatment.
    Manungo J, Thomas JE.
    Cent Afr J Med; 1982 Sep; 28(9):209-11. PubMed ID: 7151141
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Should large lesions of leprosy be considered as "multibacillary" for treatment purposes even if the total number of lesions is less than five?
    Kumarasinghe SP, Kumarasinghe MP.
    Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):173-4. PubMed ID: 15301583
    [No Abstract] [Full Text] [Related]

  • 37. Skin smears and bacterial index in multiple drug therapy.
    Agrawal MN, Porichha D.
    Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):628-30. PubMed ID: 3221121
    [No Abstract] [Full Text] [Related]

  • 38. Multidrug therapy in leprosy and its future components.
    Girdhar BK.
    Indian J Lepr; 1994 Dec; 66(2):179-208. PubMed ID: 7806900
    [No Abstract] [Full Text] [Related]

  • 39. Treatment of leprosy in the United States.
    Levis WR.
    Bull N Y Acad Med; 1984 Sep; 60(7):696-711. PubMed ID: 6386081
    [No Abstract] [Full Text] [Related]

  • 40. Relapse following fixed duration treatment for multibacillary leprosy.
    Wkly Epidemiol Rec; 1994 Oct 14; 69(41):301-2. PubMed ID: 7986699
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.